During her tenure as CEO for FrostPharma AB, Cecilia Bröms-Thell has invested and prepared the FrostPharma business for accelerated growth while securing solid performance of the in-line portfolio. The Regulatory framework and the Commercial capabilities have been strengthened and FrostPharma is now in a position to leverage and maximise its pipe-line opportunities. Cecilia Bröms-Thell has however recently decided to explore new opportunities outside of FrostPharma why she has resigned as CEO. For a period of time Cecilia has however agreed to stay on as Chief Commercial Officer effective 1 january 2022. In this new role Cecilia Bröms-Thell will continue to strengthen the FrostPharma capabilities. “On behalf of FrostPharma and the Board I want to thank Cecilia Bröms-Thell for her significant contribution to the FrostPharma business as CEO and wish her good luck in her new role within FrostPharma as Chief Commercial Officer and later in her new role outside of Frost.”
From the 1st of January 2022 Fredrik Andersch take the role of FrostPharma CEO. Fredrik Andersch brings extensive international experience to FrostPharma from senior business positions at pharmaceutical companies such as AstraZeneca and Meda. Fredrik Andersch has a proven track-record of delivering strong growth through complex organisations both in a Nordic and international setting, such as Europe and Asia. With his background Fredrik Andersch also strengthen FrostPharma business development capabilities. The experience to drive growth through both portfolio and geographic expansion will further strengthen FrostPharma in its growth journey. As Fredrik consulted for FrostPharma in 2021 he has in-depth understanding of the organisation and business model, which secure business continuity during the transition. “On behalf of FrostPharma and the Board I want to wish Fredrik Andersch good luck in his role of CEO, and I look forward to working with him going forward.”
About Frost Pharma AB
FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence.
Chairman of the Board